Immuno-Oncology | Specialty

Dr. Petrylak on FDA Approval of Pembrolizumab in Bladder Cancer

May 18th 2017

Daniel P. Petrylak, MD, professor of Medicine (Medical Oncology) and Urology, co-director, Signal Transduction Research Program, Yale Cancer Center, discusses the FDA approval of pembrolizumab (Keytruda) for the treatment of patients with bladder cancer.

FDA Approves Pembrolizumab for Urothelial Carcinoma

May 18th 2017

The FDA has granted pembrolizumab approvals in the frontline and second-line settings for urothelial carcinoma.

Dr. Black on Combinations with Durvalumab in Bladder Cancer

May 17th 2017

Peter Black, MD, senior research scientist, Vancouver Prostate Center, associate professor, Department of Urologic Sciences, University of British Columbia, discusses combination trials with durvalumab (Imfinzi) for patients with bladder cancer.

Dr. Gupta on VEGF Inhibitors Combined with Immunotherapy in Kidney Cancer

May 17th 2017

Shilpa Gupta, MD, assistant professor, Hematology Oncology and Transplantation Division, University of Minnesota, discusses combining VEGF inhibitors with immunotherapy for patients with kidney cancer.

Cleveland Clinic Researchers Explore Epigenetic Combo as Immunotherapy Booster

May 16th 2017

An epigenetic strategy under study at Cleveland Clinic combines THU, a cytidine deaminase inhibitor, with decitabine and nivolumab (Opdivo) in patients with non-small cell lung cancer. The results of early studies demonstrate that THU may help prime the immune system.

Dr. Corn on Possibility of Immunotherapy for Patients With Prostate Cancer

May 15th 2017

Paul G. Corn, MD, PhD, associate professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the possibility of immunotherapy in patients with prostate cancer.

Chemotherapy/Immunotherapy Combinations in Lung Cancer

May 12th 2017

The Changing Immunotherapy Landscape in Lung Cancer

May 12th 2017

Efficacy and Safety of Checkpoint Inhibitors in Lung Cancer

May 12th 2017

Maintenance Strategies in Lung Cancer

May 12th 2017

Lung Adenocarcinoma: The Evolving Role of Chemotherapy

May 12th 2017

Importance of Chemotherapy in Lung Cancer

May 12th 2017

Important Long-Term Considerations in Lung Cancer

May 12th 2017

Initial Treatment Approach in Lung Cancer

May 12th 2017

PD-L1 Status: What Is the Current Role?

May 12th 2017

Current and Future Biomarker Testing in Lung Cancer

May 12th 2017

Pathology and Treatment Decisions in Lung Cancer

May 12th 2017

Diagnosing Lung Adenocarcinoma: Biopsying Adequate Tissue

May 12th 2017

The Pathologic Workup of Lung Adenocarcinoma

May 12th 2017

Durvalumab Improves PFS in Phase III NSCLC Trial

May 12th 2017

Durvalumab (Imfinzi) significantly improved progression-free survival when used as a sequential treatment in patients with locally-advanced, unresectable non-small cell lung cancer who had not progressed following standard care with platinum-based chemotherapy and radiotherapy.